SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC? - 102017

Spotlight
Video

SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

VJOncology has 644 videos Subscribe Here

Loading........
Description: With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC), a question arising is which drug is better. Speaking from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses this question.
Shared By : VJOncology
Posted on : 02/12/18
Added : 4 months ago
Category : Prostate Cancer